User:Longshotpictures/Qu Biologics

Qu Biologics ... is a Biotech Company based in Vancouver in development of Site Specific Immunomodulators (SSIs) to combat a variety of inflammatory bowel disease, Crohns, Ulcerative colitis and cancer.

Qu Biologics set a goal to raise CDN$4.5 million. The financing was oversubscribed, raising a total of $5.1 million, for a total of CDN$8.2M raised in 2014 to date.

Trials for Crohns are underway and expected to be finished by September 2015.

The company has also initiated a Phase 2a clinical trial in non-small cell lung cancer.

The strategy of using dead bacteria to stimulate the adaptive portion of a person's immune system is in part due to the clinical remission of "Rob Freemans" non-Hodgkins Lymphoma after receiving a blood infection while at a Texas Hospital. Rob Freeman is an entrepreneur who sold London Telecom, a telecommunications company for $76 million in 1999. Three months later he was diagnosed and given less than 12 months to live.

The blood infection nearly killed him. But after surviving the infection, Rob's cancer went into remission. Freeman visited Gunn and learned about other cancer patients who went into remission following their infections. Convinced his own infection slowed his cancer long enough to be treated, Freeman agreed to help finance Qu Biologics and the company was born.

Qu Biologics was founded in 2007. Dr. Hal Gunn is the Co-Founder and Chief Executive Officer. Dr. Simon B. Sutcliffe is the Chief Medical Officer and Member of The Scientific Advisory Board Mr. Salim Dhanji is the Head of Pre-Clinical Research Ms. Julie Jang is the Director of Communications Dr. Robert Cory is the Vice President of Business Development

The company address is 887 Great Northern Way, Suite 150, Vancouver, BC V5T 4T5, Canada